CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BKRASMutationPredictiveSupportsResistanceLung Non-small Cell CarcinomaErlotinib,GefitinibLudovini et al., 2011
BKITExon 9 MutationPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorImatinibHeinrich et al., 2003
CPDGFRAMutationPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorImatinibHeinrich et al., 2003
BBRAFV600EPrognosticSupportsPoor OutcomePapillary Thyroid CarcinomaKim et al., 2012
CEGFRE746_A750delPredictiveSupportsSensitivity/ResponseBronchiolo-alveolar AdenocarcinomaErlotinibPao et al., 2004
BEGFRExon 19 DeletionPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaGefitinibHan et al., 2012
BEGFRMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibPao et al., 2004
DEGFRL858RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaLapatinibLi et al., 2008
DEGFRL858RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDacomitinibEngelman et al., 2007
DEGFRL858RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaNeratinibShimamura et al., 2006
DEGFRL858RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCanertinibLi et al., 2008
BEGFRL858RPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaGefitinibHan et al., 2012
CBCR::ABL1Fusion AND ABL1 M244VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
DBCR::ABL1Fusion AND ABL1 M244VPredictiveSupportsSensitivity/ResponseCancerImatinibO'Hare et al., 2005
DBCR::ABL1Fusion AND ABL1 M244VPredictiveDoes Not SupportResistanceCancerDasatinib,NilotinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 G250EPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibRedaelli et al., 2009
DBCR::ABL1Fusion AND ABL1 G250EPredictiveDoes Not SupportResistanceCancerNilotinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 Q252HPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaImatinibRedaelli et al., 2009
CBCR::ABL1Fusion AND ABL1 Q252HPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
DBCR::ABL1Fusion AND ABL1 Q252HPredictiveDoes Not SupportResistanceCancerDasatinib,NilotinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 Y253HPredictiveSupportsResistanceChronic Myeloid LeukemiaNilotinib,Imatinib MesylateBradeen et al., 2006
CBCR::ABL1Fusion AND ABL1 E255VPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
DBCR::ABL1Fusion AND ABL1 Y253FPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibO'Hare et al., 2005
DBCR::ABL1Fusion AND ABL1 Y253FPredictiveDoes Not SupportResistanceCancerBafetinib,Nilotinib,DasatinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 E255KPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibRedaelli et al., 2009
DBCR::ABL1Fusion AND ABL1 E255KPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibO'Hare et al., 2005
CBCR::ABL1Fusion AND ABL1 E355GPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
CBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
DBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceCancerNilotinib,Imatinib,Dasatinib,BafetinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 F317LPredictiveDoes Not SupportResistanceCancerBafetinib,NilotinibDeguchi et al., 2008
DABCB1OverexpressionPredictiveSupportsResistanceChronic Myeloid LeukemiaBafetinib,DasatinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 M351TPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaImatinibRedaelli et al., 2009
DBCR::ABL1Fusion AND ABL1 M351TPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaNilotinibRedaelli et al., 2009
DBCR::ABL1Fusion AND ABL1 M351TPredictiveDoes Not SupportResistanceCancerBafetinib,Dasatinib,NilotinibDeguchi et al., 2008
BTP53OverexpressionPrognosticSupportsPoor OutcomeOvarian CancerReles et al., 2001
BTP53DNA Binding Domain MutationPredictiveSupportsResistanceBreast CancerTamoxifenBerns et al., 2000
DBCR::ABL1Fusion AND ABL1 F486SPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaNilotinibRedaelli et al., 2009
DATMc.7089+1delPredictiveSupportsResistanceChronic Lymphocytic LeukemiaDoxorubicinNavrkalova et al., 2013
DATMc.7515+1_2delPredictiveSupportsResistanceChronic Lymphocytic LeukemiaDoxorubicinNavrkalova et al., 2013
DATMK293*PredictiveSupportsResistanceChronic Lymphocytic LeukemiaDoxorubicinNavrkalova et al., 2013
DATMF1025LPredictiveSupportsResistanceChronic Lymphocytic LeukemiaDoxorubicinNavrkalova et al., 2013
DATME2187*PredictiveSupportsResistanceChronic Lymphocytic LeukemiaDoxorubicinNavrkalova et al., 2013
DATML2427PPredictiveSupportsResistanceChronic Lymphocytic LeukemiaDoxorubicinNavrkalova et al., 2013
DATMF2732VPredictiveSupportsResistanceChronic Lymphocytic LeukemiaDoxorubicinNavrkalova et al., 2013
DATMD1682HPredictiveSupportsResistanceChronic Lymphocytic LeukemiaDoxorubicinNavrkalova et al., 2013
DATMA2062VPredictiveSupportsResistanceChronic Lymphocytic LeukemiaDoxorubicinNavrkalova et al., 2013
DATMC2488YPredictiveSupportsResistanceChronic Lymphocytic LeukemiaDoxorubicinNavrkalova et al., 2013
DBCR::ABL1Fusion AND ABL1 E255VPredictiveSupportsResistanceChronic Myeloid LeukemiaNilotinibRedaelli et al., 2009
DBCR::ABL1Fusion AND ABL1 V299LPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaNilotinibRedaelli et al., 2009
DBCR::ABL1Fusion AND ABL1 G398RPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaNilotinibRedaelli et al., 2009
Page 41 of 96
PreviousNext